Skip to main content

Table 5 Cost-effectiveness (CHF per patient) of VN versus SoC, discounted

From: Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland

Effectiveness

SoC

VN

Difference

Blindness-free yearsa

20.65

28.32

7.67

Quality-adjusted survival (QALYs)

11.62

18.35

6.73

Costs

VN treatment

0

768’087

768’087

Eligibility testing (viable retinal cells)

0

493

493

Adverse events

0

768

768

Health care resource useb

137’252

132’305

-4’947

Total costs, healthcare system perspective

137’252

901’654

764’402

Incremental cost effectiveness, health care system perspective (base case)

ICER (CHF per blindness-free year gained)a

99,603

ICER (CHF per QALY gained)

113’526

  1. a Counting health state HS5 as ‘blindness’.
  2. b Including costs of technical assistance, community care and residential care.
  3. KEY: CHF Swiss francs, ICER incremental cost-effectiveness ratio, QALYs quality-adjusted life years, SoC standard of care, VN voretigene neparovec.